Pharmaceutical giant

制药巨头

Novo Nordisk

诺和诺德

is discontinuing the country's largest selling insulin,

正在停止销售该国销量最大的胰岛素，

Human Mixtard

人用混合胰岛素

, along with other insulins. The move could shake up the diabetes market, TOI reported.

，以及其他胰岛素产品。此举可能会撼动糖尿病市场，《印度时报》报道。

Despite it being under price control, Human Mixtard alone is a Rs 800 crore brand for the company in India. The phase out could further impact the pharmaceutical's top brands in the Rs 5,000 crore insulin market including Actrapid,

尽管受到价格控制，但仅Human Mixtard这一款产品在印度市场上就为公司带来了80亿卢比的收入。逐步淘汰可能会进一步影响其在500亿卢比胰岛素市场中的顶级品牌，包括Actrapid。

Insulatard

胰岛素注射液

, Insulin Detemir and Levemir and Xultophy, which are marketed primarily in the format of pre-filled disposable pen and cartridges (Penfill and FlexPen).

，主要以预填充一次性笔和卡式瓶（Penfill和FlexPen）的形式销售的德谷胰岛素、地特胰岛素、Levemir和Xultophy。

TOI accessed documents that said the company recently informed marketing partner,

《印度时报》查阅的文件显示，该公司最近通知营销合作伙伴，

Abbott India

印度雅培

that the products would be discontinued once the current stocks are exhausted. This could take about six months.

一旦现有库存耗尽，这些产品将停止供应。这个过程可能需要大约六个月的时间。

The decision comes as the Danish company's global strategy to prioritise newer, patented diabetes and weight loss therapies including Ozempic and Wegovy, due to their higher profitability, sources told TOI. It also is in line with its plans to introduce these therapies in the Indian market this year..

该决定是这家丹麦公司的全球战略，即优先考虑更新的、已获专利的糖尿病和减肥疗法（包括 Ozempic 和 Wegovy），因为它们的盈利能力更高，消息人士告诉《印度时报》。这也符合该公司计划今年在印度市场推出这些疗法的计划。

Novo Nordisk, as a part of its global strategy is discontinuing earlier generation insulin products gradually.

诺和诺德作为其全球战略的一部分，正在逐步停止早期的胰岛素产品。

Live Events

现场活动

However, the company plans to continue selling Human Mixtard, Actrapid and Insulatard, in vials, which can be delivered to patients through injections.

然而，该公司计划继续销售瓶装的人混合胰岛素、速效胰岛素和中效胰岛素，这些药物可以通过注射方式提供给患者。

This might lead to limited access as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected with syringes, due to its accuracy, ease of dosing, and reduced stigma.

这可能会导致获取途径受限，因为绝大多数糖尿病患者更喜欢使用胰岛素笔而非注射器注射药瓶中的胰岛素，原因是胰岛素笔具有精确、易于控制剂量和减少病耻感的优势。

(With TOI inputs)

（来自TOI的输入）

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)